Sylvester Comprehensive Cancer Center Report issue

Academic/Hospital Phase 1 Phase 3

Organization Overview

First Clinical Trial
2016
NCT02853604
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Sylvester Comprehensive Cancer Center

Active Ingredients

Drugs in Phase 3 Trials (1)

adxs11-001 (1 trial)

Drugs in Phase 1 Trials (5)

docetaxel (taxotere) (1 trial)

gemcitabine (gemzar) (1 trial)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (1 trial)

ttx-030 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Uterine Cervical Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 6